Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Liquid Biopsy to Screen for Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma: the EMERALD Multi-center Study.

NCT06381583 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT06381583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06381583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Liquid Biopsy to Screen for Barrett's Esophagus, Dysplasia, and Esophageal Adenocarcinoma: the EMERALD Multi-center Study.
Lead sponsor
City of Hope Medical Center
Phase
Observational
Overall status
Completed
Start date
April 15, 2023
Completion date
April 24, 2024
Enrollment
658 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

barrett adenocarcinoma, barrett epithelium, barrett esophagus, barrett esophagus, long-segment, barrett's esophagus with dysplasia, unspecified, barrett's esophagus with esophagitis, barrett's esophagus without dysplasia, barretts esophagus with dysplasia, barretts esophagus with high grade dysplasia, barretts esophagus with low grade dysplasia, esophageal adenocarcinoma, esophageal cancer, esophageal cancer stage, esophageal dysplasia, esophageal neoplasms, esophageal neoplasms malignant, esophagus adenocarcinoma, esophagus cancer, esophagus, barrett, gastroesophageal reflux, reflux disease